New drug cocktail shows promise for tough leukemia
NCT ID NCT03900949
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 35 times
Summary
This early-stage study tested whether adding two targeted drugs (gemtuzumab ozogamicin and midostaurin) to standard chemotherapy is safe for people with a specific type of acute myeloid leukemia (FLT3-mutated AML). 21 newly diagnosed adults took part. The goal was to find the best dose and check for side effects. While the combination aims to improve treatment, patients still need ongoing management, so this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University Knight Cancer Institute - Northwest Portland
Portland, Oregon, 97210, United States
Conditions
Explore the condition pages connected to this study.